Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06300411 · ClinicalTrials.gov registry record · Phase 1
SRG-514 Administered Intraoperatively to Patients Undergoing Breast-conserving Cancer Surgery
A Phase 1 study of Breast Cancer, sponsored by SURGE Therapeutics.
- Active
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
- 8
- Study locations
NCT06300411: Active Phase 1 study of Breast Cancer, sponsored by SURGE Therapeutics.
NCT06300411 is a Phase 1 study of Breast Cancer that is active but no longer recruiting, run by SURGE Therapeutics. The registered enrollment target is 24 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (99% lower). The trial reports 8 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06300411, a Phase 1 study of Breast Cancer, is active but no longer recruiting, sponsored by SURGE Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
- 8
- Study locations
Study Summary
This is a multicenter, first-in-human (FIH), open label, Phase 1 dose escalation and recommended Phase 2 dose (RP2D) extension trial with a primary objective to define the RP2D of SRG-514 when administered intraoperatively to patients undergoing breast-conserving cancer surgery. SRG-514 will be investigated utilizing a 3+3 convention dose escalation cohorts.
Primary Outcome
Incidence of dose-limiting toxicities (DLTs) over the first 14-days of study treatment
Conditions Studied
Interventions
- DRUG SRG-514
Study Locations (8)
Texas
- MD Anderson Cancer Center - Houston
- Audie Murphy VA - San Antonio
Georgia
- Memorial Health - Savannah
Indiana
- Indiana University - Indianapolis
Minnesota
- Mayo - Rochester
Missouri
- Washington University School of Medicine - St Louis
New York
- NYU Langone Health - New York
North Carolina
- Duke Cancer Center - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2024-07-29 |
| Est. Completion | 2026-04-10 |
| Phase | Phase 1 |
What the registry record for NCT06300411 still lists
NCT06300411 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which SRG-514 is the first listed.
NCT06300411 lists 8 locations in 7 states (Texas, Georgia, Indiana).
Frequently Asked Questions
What is clinical trial NCT06300411 about?
NCT06300411 is a clinical study titled "SRG-514 Administered Intraoperatively to Patients Undergoing Breast-conserving Cancer Surgery". This is a multicenter, first-in-human (FIH), open label, Phase 1 dose escalation and recommended Phase 2 dose (RP2D) extension trial with a primary objective to define the RP2D of SRG-514 when administered intraoperatively to patients undergoing breast-conserving cancer surgery. SRG-514 will be inve...
What is the current status of trial NCT06300411?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2024-07-29. Estimated completion is 2026-04-10.
What conditions does trial NCT06300411 study?
This clinical trial studies the following conditions: Breast Cancer.
What interventions are being tested in trial NCT06300411?
The interventions under investigation include: SRG-514 (DRUG).
Who is sponsoring clinical trial NCT06300411?
This trial is sponsored by SURGE Therapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06300411 being conducted?
This trial has 8 study locations across Georgia, Indiana, Minnesota, Missouri, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06300411's enrollment target sits among peer trials
24 1042nd of 1224 higher than 170 of 1,224 other Breast Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
VS-6766+Abema+Fulv in Met HR+/HER- BC
RECRUITING · Phase 1
-
KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer
RECRUITING · Phase 1
-
Focused Ultrasound and Gemcitabine in Breast Cancer
RECRUITING · Phase 1
-
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI